The UK’s Technology Strategy Board has awarded Nemaura a research grant to evaluate the market potential for the company’s acne management and prevention system. The grant will be used to explore whether it is feasible to use one of Nemaura’s transdermal device systems to treat acne. “The system works to clear the blocked pores where sebum and oils can gather and lead to the development of acne”, explained Dr Faz Chowdhury, CEO of Nemaura Pharma. “It is completely drug-free and does not use any aggressive chemicals”.
Almost 90% of teenagers have acne. Contrary to popular belief, symptoms frequently linger into adulthood. Permanent scarring is common and the condition can have an extremely detrimental effect on quality-of-life. The psychological effects include anxiety and depression. “Although various acne treatments are available, they have limited effect for people with certain skin types (ie large pores, and oily skin)”, said Dr Chowdhury. For these individuals, and for those with severe acne, systemic isotretinoin is commonly prescribed. But isotretinoin has serious side effects associated with longer-term systemic use.
“There are significant market opportunities for innovative strategies that offer acne treatment without the use of chemicals and without imposing side effects”, added Dr Chowdhury. “Preferably novel methods should be user friendly and tailored to use in the comfort of the patient’s home”. Nemaura’s patches, which use the company’s proprietary transdermal technology, offer such advantages. The Technology Strategy Board grant will help determine whether the system could be used to help alleviate the symptoms of those who suffer from the consequences of acne.
Addendum
After successful completion of the project, it was concluded that there was clear potential for using the transdermal device system to treat some forms of acne, and that this should be further substantiated through a clinical programme. Nemaura plans to undertake such a programme in the near future.
Cautionary Statement Regarding Forward Looking Statements.
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations, and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Nemaura’s ongoing studies, including the safety and efficacy of Nemaura’s matrix transdermal patch technology, the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell the matrix transdermal patch technology, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its matrix transdermal patch technology.
Nemaura undertakes no obligation to publicly update or revise any forward-looking statements.